AtaiBeckley (ATAI) Reports Phase 2a Data in CNS Drugs

AtaiBeckley Inc. (NASDAQ:ATAI) secured a spot on our list of the best penny stocks set to explode.

AtaiBeckley (ATAI) Reports Phase 2a Data in CNS Drugs

Pixabay/Public Domain

AtaiBeckley Inc. (NASDAQ:ATAI) published peer-reviewed Phase 2a data in CNS Drugs on April 8, 2026. The company highlighted patients with treatment-resistant depression who continued on stable SSRI therapy with a single intranasal dose of BPL-003, experiencing quick and long-lasting antidepressant benefits. The company noted Day 2 response rates of 66.7% for both the 10 mg and 12 mg groups, while durability through Week 12 was 83% in the 10 mg group and 66.7% in the 12 mg group.

According to AtaiBeckley Inc. (NASDAQ:ATAI), Phase 3 remains scheduled for Q2 2026 following FDA End-of-Phase 2 alignment, with the drug being well-tolerated with no noteworthy side effects.

Earlier, on March 27, 2026, Deutsche Bank began covering AtaiBeckley Inc. (NASDAQ:ATAI) with a ‘Buy’ rating and a $12 price target, claiming that the company is well-positioned to become a market leader in psychedelic medicines, with BPL-003 and VLS-01 addressing a significant unmet need in treatment-resistant depression.

AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company that researches, develops, and commercializes mental health treatments in the US, Germany, and Canada.

While we acknowledge the risk and potential of ATAI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ATAI and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.